GO
Loading...

Neurocrine Biosciences CEO on TD treatment

Tuesday, 7 Jan 2014 | 2:35 PM ET

Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.